Skip to main content

Table 1 Patients’ characteristics by study phase

From: A multidisciplinary team-oriented intervention to increase guideline recommended care for high-risk prostate cancer: A stepped-wedge cluster randomised implementation trial

Characteristic Study phase
Control Transition Intervention Total:  
n (%) n (%) n (%) N (%) p value^
All patients: 505 (100%) 159 (100%) 407 (100%) 1071 (100%)  
Age
 Median (years) 65.0 65.0 65.0 65.0  
 Quartiles (years) 59–68 58–69 61–69 60–69  
Age group
 40–59 128 (25%) 43 (27%) 81 (20%) 252 (24%) 0.145
 60–69 284 (56%) 84 (53%) 231 (57%) 599 (56%)  
 70+ 93 (18%) 32 (20%) 95 (23%) 220 (21%)  
Extracapsular extension
 No 96 (19%) 27 (17%) 69 (17%) 192 (18%) 0.511
 Yes 406 (80%) 131 (82%) 338 (83%) 875 (82%)  
 Unsure 3 (1%) 1 (1%) 0 (0%) 4 (0%)  
Positive surgical margin
 No 229 (45%) 69 (43%) 198 (49%) 496 (46%) 0.087
 Yes 276 (55%) 89 (56%) 204 (50%) 569 (53%)  
 Unsure 0 (0%) 1 (1%) 5 (1%) 6 (1%)  
Seminal vesicle invasion
 No 395 (78%) 131 (82%) 339 (83%) 865 (81%) 0.231
 Yes 109 (22%) 28 (18%) 66 (16%) 203 (19%)  
 Unsure 1 (0%) 0 (0%) 2 (0%) 3 (0%)  
Regional lymph node involvement
 No 305 (60%) 98 (62%) 278 (68%) 681 (64%) 0.035
 Yes 30 (6%) 5 (3%) 25 (6%) 60 (6%)  
 Unsure 170 (34%) 56 (35%) 104 (26%) 330 (31%)  
Post-operative Gleason grade
 6–7 395 (78%) 133 (84%) 344 (85%) 872 (81%) 0.132
 8 30 (6%) 3 (2%) 18 (4%) 51 (5%)  
 9–10 77 (15%) 22 (14%) 42 (10%) 141 (13%)  
 Unsure 3 (1%) 1 (1%) 3 (1%) 7 (1%)  
Number of co-morbidities
 0 103 (20%) 19 (12%) 70 (17%) 192 (18%) 0.050
 1 72 (14%) 19 (12%) 45 (11%) 136 (13%)  
 2 74 (15%) 23 (14%) 49 (12%) 146 (14%)  
 3+ 256 (51%) 98 (62%) 243 (60%) 597 (56%)  
Maximum PSA level within 4 months after RP (ng/ml)
  < 0.1 399 (79%) 137 (86%) 339 (83%) 875 (82%) 0.224
  ≥ 0.1 83 (16%) 16 (10%) 51 (13%) 150 (14%)  
 No PSA test recorded 23 (5%) 6 (4%) 17 (4%) 46 (4%)  
Site
 Site 1 27 (5%) 14 (9%) 48 (12%) 89 (8%) < 0.001
 Site 2 11 (2%) 2 (1%) 12 (3%) 25 (2%)  
 Site 3 68 (13%) 39 (25%) 120 (29%) 227 (21%)  
 Site 4 51 (10%) 12 (8%) 54 (13%) 117 (11%)  
 Site 5 23 (5%) 3 (2%) 19 (5%) 45 (4%)  
 Site 6 77 (15%) 21 (13%) 36 (9%) 134 (13%)  
 Site 7 81 (16%) 26 (16%) 34 (8%) 141 (13%)  
 Site 8 120 (24%) 26 (16%) 52 (13%) 198 (18%)  
 Site 9 47 (9%) 16 (10%) 32 (8%) 95 (9%)  
  1. Data are n (%) unless otherwise stated, ^p values are for differences in % across the three groups from chi-squared tests